Longboard Pharmaceuticals

By |2021-06-17T17:15:43-05:00June 3rd, 2021|Categories: 2021 Virtual Tote Group 2|

Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, with an initial focus on rare diseases.  Our lead asset, LP352, is an oral, centrally acting, 5-HT2c superagonist in development for the potential treatment of developmental and epileptic encephalopathies (DEEs) such as Dravet syndrome, Lennox-Gastaut syndrome (LGS) and other [...]

Biocodex

By |2021-06-15T15:52:27-05:00June 3rd, 2021|Categories: 2021 Virtual Tote Group 2|

Biocodex is a family-owned multinational pharmaceutical company founded in France in 1953, with proven expertise in treatments for the central nervous system. We are dedicated to providing education and support in the field of Dravet syndrome to healthcare providers, affected individuals, and their families. Navigating Life with Dravet Syndrome

Epygenix

By |2021-06-14T19:08:51-05:00June 1st, 2021|Categories: 2021 Virtual Tote Group 2|

Epygenix Therapeutics is a clinical stage precision medicine-based biopharmaceutical company developing drugs for rare and intractable forms of genetic epilepsy, such as Dravet syndrome and Lennox-Gastaut syndrome. Journey from Aquarium-to-Bedside to Treat Genetic Epilepsies The ARGUS (EPX-100; Clemizole HCI) trial is currently recruiting. More information on this multi-national, multi-center trial may be found on clinicaltrials.gov. [...]

UCB

By |2021-06-15T15:08:53-05:00June 1st, 2021|Categories: 2021 Virtual Tote Group 2|

At UCB, we come together every day laser-focused on a simple question: How will this create value for people living with severe diseases? We are a global biopharmaceutical company committed to innovation to improve the lives of people with neurological and immunological diseases, finding solutions to meet their unique needs. Seizure Diary Infographic on Seizure [...]

Stoke Therapeutics

By |2021-06-16T07:57:12-05:00June 1st, 2021|Categories: 2021 Virtual Tote Group 2|

Stoke Therapeutics is a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines. Using the Company’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. The Company’s first compound, STK-001, is in clinical testing for [...]

Go to Top